A phase II study of alternating sunitinib and temsirolimus therapy in patients with metastatic renal cell carcinoma.
Sign Up to like & getrecommendations! Published in 2023 at "Cancer medicine"
DOI: 10.1002/cam4.5990
Abstract: BACKGROUND Sunitinib is a multi-target tyrosine kinase inhibitor (TKI) that inhibits VEGF receptor 1, 2, 3 (VEGFRs), platelet-derived growth factor receptor (PDGFR), colony-stimulating factor receptor (CSFR), and the stem cell factor receptor c-KIT. Temsirolimus inhibits… read more here.
Keywords: alternating sunitinib; cell; metastatic renal; therapy ... See more keywords